EPO and sarcoma: Particularly, B7-H3 was strongly upregulated across the entire spectrum of sarcoma EPO-GEMMs (Supplementary Fig. 7b, g), further supporting ongoing clinical approaches of anti-B7-H3 immunotherapy in solid tumors.